Accumulation of porphyrins in plasma and tissues of dogs after δ-aminolevulinic acid administration: Implications for photodynamic therapy

Pharmacology

Volumn 52, Issue 6, 1996, Pages 362-370

  Eggeri, Norman G ^a,c   Motamedi, Massoud ^b,c   Pow Sang, Mariela ^b   Orihuela, Eduardo ^b   Anderson, Karl E ^a  

^a Preventive Medicine and Community Health   (United States)

^b Departments of Pediatrics   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cancer; Photodynamic therapy; Porphyrins; Protoporphyrin; Aminolevulinic acid

Indexed keywords

AMINOLEVULINIC ACID; COPROPORPHYRIN; PHOTOSENSITIZING AGENT; PORPHOBILINOGEN; PORPHYRIN; PROTOPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; INTRAVENOUS DRUG ADMINISTRATION; LIVER LEVEL; MALE; NONHUMAN; PANCREAS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE; TISSUE LEVEL; TUMOR NECROSIS; URINE LEVEL;

AMINOLEVULINIC ACID; ANIMALS; COPROPORPHYRINS; DOGS; LIVER; MALE; NEOPLASMS; PANCREAS; PHOTOCHEMOTHERAPY; PORPHYRINS; PROSTATE;

EID: 0029824659     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139403     Document Type: Article

References (26)

1. Van Hillcgershcrg R, Kon W, Wilson J: Current status of photodynamic therapy in oncology, Drugs 1994:48:510-527.
2. Pass HI: Photodynamic therapy in oncology-Mechanisms and clinical use, J Natl Cancer Inst 1993:85: 443-456.
3. Kessel D: Photodynamic therapy and neoplastic disease, Oncol Res 1992;4:219-225.
4. Dougherty TJ, Marcus SL: Photodynamic therapy, Eur J Cancer 1992: 28A: 1734-1742.
5. Dougherty TJ, Cooper MT, Mang TS: Cutaneous phototoxic occurrences in patients receiving Photo-frin, Lasers Surg Med 1990:10:485-488.
6. Anderson K, Drummond G, Fred-dara U, Sardana M, Sassa S: Por-phvrogenic effects and induction of heme oxygenase in vivo by 8-amino-levulinic acid, Biochim Biophys Acta 1981;676:289-299.
7. Kennedy JC, Pottier RH: Endogenous protoporphyrin-IX, a clinically useful photosensitizer for photodynamic therapy, J Photochem Photo-biolB 1992:14:275-292.
8. Bedwell J, MacRoberl AJ, Phillips D, Brown SG: Fluorescence distribution and photodynamic effect of ALA induced PPIX in the DMH rat colonic tumour model, Br J Cancer 1992;65:818-824.
9. Loh CS, Bedwell J, MacRobcrt AJ, Krasner N, Phillips D, Brown SG: Photodynamic therapy of the normal rat stomach: A comparative study between di-sulphonatcd aluminium phthalocyaninc and 5-ami-nolaevulinic acid, BrJ Cancer 1992; 66:452-462.
10. Peng Q, Moan J, Warloc T, Nesland JM, Rimington C: Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolcvulinic acid in mice bearing mammary carcinoma, Int J Cancer 1992;52:433-443.
11. Loh CS, Vernon D, MacRobcrt AJ, Bedwell J, Bown SG, Brown SB: Endogenous porphyrin distribu'.ion induced by 5-aminolaevulinic acid in the tissue layers of the gastrointestinal tract, J Photochem Photobiol B 1993;20:47-54.
12. Pottier RH, Chow YFA, LaPlante JP, Truscott TG, Kennedy JC, Bei-ner LA: Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo, Photochem Photobiol 1986:44:679-687.
13. Van Hillegersberg R, Van den Berg JWO, Kort WJ, Tcrpstra OT, Wilson JHP: Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats, Gastroenterology 1992; 103:647-651.
14. Kondo T, Kuchiba K, Shimizu Y: Metabolic fate of exogenous delta-aminolevulinic acid in Dubin-John-son syndrome, J Lab Clin Med 1979;94:421-428.
15. Shimizu Y, Ida S, Naruto H, Urata G: Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid, J Lab Clin Med 1978;92:795-802.
16. Mustajoki P, Timoncn K, Gorchein A, Scppalainen AM, Matikainen E: Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: No porphyric symptoms, Eur J Clin Invest 1992:22:407-411.
17. Anderson KE: Effects of antihypertensive drugs on hepatic heme biosynthesis, and evaluation of ferro-chelatase inhibitors to simplify testing of drugs for heme pathway induction, Biochim Biophys Acta 1978;543:313-327.
18. Schwartz S, Edmondson P, Stephenson B, Sarkar D, Freyholtz H: Direct spectrofiuorophotomctric determination of porphyrin in diluted urine, Ann Clin Res 1976;8:156-161.
19. Mauzerall D, Granick S: The occurrence and determination of 8-ami-nolevulinic acid and porphobilinogen in urine, J Biol Chem 1956:219: 435-446.
20. Bauer J: Clinical Laboratory Methods, St Louis, Mosby, 1982.
21. Kennedy SW, Wigficld DC, Fox GA: Tissue porphyrin pattern determination by high-speed high-performance liquid chromatography, Anal Biochcm 1986;157:1-7.
22. Lint CK, Pctcrs TJ: Urine and faecal porphyrin profiles by reversed-phasc high-performance liquid chromatography in the porphyrias, Clin ChimActa 1984;139:55-63.
23. Fukuda H, Paredes S, Batllc AMD: Tumour-localizing properties of porphyrins: In vivo studies using free and liposome encapsulated aminolevulinic acid, Comp Biochcm Physiol 1992;102:433-436.
24. Fukuda H, Paredes S, Casas A, Chueke F, Batllc AMD: Potential of liposome-entrapped aminolevulinic acid in cancer therapy, Effect of prior injection of empty liposomes and different routes of administration, Cancer J 1992:5/5:295-299.
25. Loh CS, MacRobert AJ, Bedwell J, Krasner N, Bown SG: Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy, Br J Cancer 1993:68: 41-51.
26. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG: Photodynamic therapy of oral cancer: Photosensitisation with systemic aminolacvulinic acid, Lancet 1993: 342:147-148.